Masing H, Bengel H J
Arzneimittelforschung. 1980;30(10):1785-7.
In 35 test persons with normal nasal condition the newly developed imidazole derivative 2-(2-imidazolin-2-yl)-N-(4-indanyl)amine hydrochloride (indanazoline E-VA-16, active principle of Farial) was tested for its decongesting influence on nasal mucosa and for its tolerability using anterior rhinomanometric techniques and comparing the results with those of xylometazoline. 10 min after application of either drug the stream volume increased significantly thus evidencing decongestion of the nasal mucosa. There was no substantial difference between the two substances. 8 h after application the initial values were virtually reached again in both treated groups. Since indanazoline showed little effect in conditions of minor respiratory resistance but was highly effective against increased initial respiratory resistance it is concluded that its therapeutic safety margin might be larger. The reactive hyperemia observed after both drugs should not be overvalued. Blood pressure and pulse rate were not appreciably influenced at any time. Both drugs were well tolerated.
在35名鼻腔状况正常的受试者中，使用前鼻测压技术，对新开发的咪唑衍生物2-(2-咪唑啉-2-基)-N-(4-茚满基)胺盐酸盐（茚达唑啉E-VA-16，法里亚尔的活性成分）对鼻黏膜的减充血作用及其耐受性进行了测试，并将结果与赛洛唑啉的结果进行比较。使用两种药物中的任何一种后10分钟，气流体积显著增加，从而证明鼻黏膜充血减轻。两种物质之间没有实质性差异。用药8小时后，两个治疗组的初始值几乎再次达到。由于茚达唑啉在轻度呼吸阻力情况下效果不佳，但对初始呼吸阻力增加具有高效作用，因此得出结论，其治疗安全范围可能更大。两种药物后观察到的反应性充血不应被高估。血压和脉搏率在任何时候都没有受到明显影响。两种药物耐受性良好。
